Nanobac Pharmaceuticals, Incorporated (NNBP) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNanobac Pharmaceuticals, Incorporated (NNBP) trades at $0.0001. Nanobac Pharmaceuticals, Incorporated focuses on the detection and treatment of calcifying nanoparticles (CNPs) to improve human health. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for NNBP: NNBP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Nanobac Pharmaceuticals, Incorporated (NNBP) Healthcare & Pipeline Overview
Nanobac Pharmaceuticals, Incorporated, a biotechnology company, specializes in developing and marketing in vitro diagnostic kits for detecting calcifying nanoparticles (CNPs). Its focus on CNP detection and treatment positions it within the niche market of urological and cardiovascular disease research, operating with a small team in Tampa, Florida.
What Is the Investment Thesis for NNBP?
Nanobac Pharmaceuticals, Incorporated presents a highly speculative investment opportunity due to its focus on the niche area of calcifying nanoparticle (CNP) detection and treatment. The company's small scale, reflected in its one-employee operation, and negative profit margin of -37319.7% highlight the significant risks involved. Potential value drivers include successful development and commercialization of CNP-targeted therapies or diagnostic tools. However, the company's OTC listing and limited financial information necessitate thorough due diligence. The high beta of -35.70 suggests extreme volatility. Any positive news regarding clinical trial outcomes or regulatory approvals could act as catalysts. Investors should carefully weigh the potential rewards against the substantial risks associated with this micro-cap biotechnology company.
Based on FMP financials and quantitative analysis
NNBP Key Highlights
Market capitalization of $0.00B indicates the company's micro-cap status and limited market presence.
- Gross margin of 17.6% demonstrates some ability to generate profit from its products, but this is offset by high operating costs.
- Profit margin of -37319.7% reflects significant losses and the challenges in achieving profitability.
- Beta of -35.70 suggests an inverse correlation to the market and extreme volatility, which is unusual and may indicate data errors.
- The company's focus on CNPs positions it in a niche market within biotechnology, potentially offering specialized opportunities if CNP research advances.
Who Are NNBP's Competitors?
NNBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NNBP's Key Strengths?
Specialized expertise in calcifying nanoparticles (CNPs).
- Proprietary diagnostic assays (NANO-CAPTURE, NANO-SERO).
- Focus on urological and cardiovascular disease research.
- Established presence in the niche CNP market.
What Are NNBP's Weaknesses?
Limited financial resources and small team size.
- High dependence on diagnostic kit sales.
- Negative profit margin and history of losses.
- OTC listing and associated risks.
What Are the Key Risks for NNBP?
Financial-distress signal — its Altman Z-Score of -8.35 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger biotechnology and pharmaceutical companies.
- Regulatory hurdles and clinical trial failures.
- Limited financial resources and high operating costs.
- Dependence on diagnostic kit sales and limited revenue streams.
- OTC listing and associated risks of illiquidity and lack of transparency.
What Threats Does NNBP Face?
- Competition from larger biotechnology and pharmaceutical companies.
- Regulatory hurdles and clinical trial risks.
- Limited market acceptance of CNP-based diagnostics and therapies.
- Economic downturns and reduced healthcare spending.
What Are NNBP's Competitive Advantages?
- Specialized Expertise: Deep understanding of calcifying nanoparticles (CNPs) and their role in various diseases.
- Proprietary Diagnostic Assays: Unique in vitro diagnostic (IVD) kits like NANO-CAPTURE and NANO-SERO.
- Research and Development: Ongoing research efforts to expand the applications of CNP technologies.
- Intellectual Property: Patents and trademarks protecting its diagnostic and therapeutic innovations.
What Does NNBP Do?
Founded in 1994 and rebranded in 2002, Nanobac Pharmaceuticals, Incorporated is dedicated to improving human health through the detection and treatment of calcifying nanoparticles (CNPs). The company manufactures and markets in vitro diagnostic (IVD) kits, including assays, antibodies, and reagents, designed for the specific detection of CNPs. These diagnostic tools, marketed under names like NANO-CAPTURE and NANO-SERO, are crucial for researchers and clinicians studying the role of CNPs in various diseases. Beyond diagnostics, Nanobac Pharmaceuticals also invests in research and clinical studies focused on understanding and addressing the impact of CNPs on urological and cardiovascular health. This includes investigations into conditions such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as various cardiovascular ailments. Based in Tampa, Florida, Nanobac Pharmaceuticals operates with a small team, reflecting its stage as a specialized biotechnology firm focused on a specific area of medical research and diagnostics. The company's evolution from HealthCentrics Inc. to Nanobac Pharmaceuticals underscores its commitment to pioneering solutions in the CNP field.
What Products and Services Does NNBP Offer?
- Discovers and develops products for detecting and treating calcifying nanoparticles (CNPs).
- Manufactures and markets in vitro diagnostic (IVD) kits for CNP detection.
- Offers diagnostic assays, including NANO-CAPTURE and NANO-SERO.
- Conducts research and clinical studies in urological diseases.
- Investigates CNPs' role in chronic prostatitis/chronic pelvic pain syndrome.
- Studies the impact of CNPs on kidney stones and polycystic kidney diseases.
- Researches the connection between CNPs and cardiovascular diseases.
How Does NNBP Make Money?
- Generates revenue through the sale of in vitro diagnostic (IVD) kits.
- Commercializes diagnostic assays like NANO-CAPTURE and NANO-SERO.
- Conducts research and development to create new products and services.
- Potentially licenses its technologies or forms strategic partnerships.
What Industry Does NNBP Operate In?
Nanobac Pharmaceuticals, Incorporated operates within the biotechnology industry, a sector characterized by high research and development costs, regulatory hurdles, and potential for significant growth. The company's focus on calcifying nanoparticles (CNPs) places it in a niche segment of this industry, targeting diagnostic and therapeutic solutions for urological and cardiovascular diseases. The broader biotechnology market is driven by innovation in genomics, personalized medicine, and novel drug delivery systems. Competition includes larger pharmaceutical and diagnostic companies, as well as specialized biotech firms. Nanobac's success depends on its ability to secure funding, navigate regulatory pathways, and demonstrate the clinical efficacy of its CNP-related technologies.
Who Are NNBP's Key Customers?
- Research institutions studying calcifying nanoparticles.
- Clinical laboratories performing diagnostic testing.
- Hospitals and medical centers treating urological and cardiovascular diseases.
- Pharmaceutical companies interested in CNP-targeted therapies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Nanobac Pharmaceuticals, Incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tampa, US. The company is led by CEO John Stanton. NNBP has traded publicly since 1994.
Key Financial Metrics
Return on equity for Nanobac Pharmaceuticals, Incorporated stands at 358.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -91.1%, showing how much profit it generates from its asset base. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Nanobac Pharmaceuticals, Incorporated's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.35 places it in the distress zone, a signal of elevated financial risk.
NNBP Financials
NNBP Latest News
No recent news available for NNBP.
NNBP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NNBP.
Price Targets
Wall Street price target analysis for NNBP.
NNBP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NNBP; grades run from A+ (80-100) to F (below 30).
Leadership: John Stanton
CEO
John Stanton serves as the CEO of Nanobac Pharmaceuticals, Incorporated, managing a small team. His leadership is focused on guiding the company's research and development efforts in the field of calcifying nanoparticles (CNPs) and overseeing the manufacturing and marketing of in vitro diagnostic kits.
Track Record: Due to limited information, specific achievements, strategic decisions, and company milestones under John Stanton's leadership cannot be detailed. His tenure and impact on the company's performance require further data and analysis.
NNBP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nanobac Pharmaceuticals, Incorporated may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may have less stringent corporate governance standards.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Lack of regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Focus on a specific niche market (calcifying nanoparticles).
- Development of proprietary diagnostic assays (NANO-CAPTURE, NANO-SERO).
- Ongoing research and development efforts.
- Established presence in Tampa, Florida.
- Operating since 1994.
NNBP Healthcare Stock FAQ
What do analysts say about NNBP stock?
As of 2026-03-17, there is no available analyst coverage or consensus on Nanobac Pharmaceuticals, Incorporated (NNBP) stock. This is likely due to the company's micro-cap status and OTC listing, which typically receive less attention from major research firms.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC market carries higher risks than major exchanges.